Topical Collection "The Safety and Immunogenicity of the Bivalent Omicron-Containing mRNA-1273.214 Booster Vaccine"

A topical collection in Vaccines (ISSN 2076-393X). This collection belongs to the section "Vaccine Efficacy and Safety".

Viewed by 1726


E-Mail Website
Collection Editor
Regional Biocontainment Laboratory (RBL), Center for Predictive Medicine, University of Louisville, Louisville, KY 40292, USA
Interests: infection and immunity; immunotherapy; check-point inhibitors and stimulators; T cell response against SARS-CoV-2; viral immunity; translational research; clinical trials; bacterial and viral vaccines; immune mechanism behind antivirals; host-pathogen immunology
Special Issues, Collections and Topics in MDPI journals
Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA
Interests: human infectious diseases; viral infections; B- and T-cell immunology; vaccine/therapeutic development; mouse model development
Special Issues, Collections and Topics in MDPI journals

Topical Collection Information

Dear Colleagues,

A bivalent vaccine from Moderna based on omicron BA.1 was approved for use as a booster dose by the Medicines and Healthcare Products Regulatory Agency. Preliminary data indicated that the vaccine generates a strong immune response against the BA.4 and BA.5 subvariants, which are now dominant worldwide. This new proposal behaves in the same manner as a flu-like situation, where everyone must take their flu vaccine at the start of winter each year and the composition of the vaccine is regularly modified in accordance with circulating strains. The new vaccines are highly effective in preventing disease severity but not transmission. We are pleased to invite you to submit to this Topical Collection for all kinds of manuscripts, such as research articles, brief reports, and communications to promote the knowledge and discussion about COVID-19 vaccines, especially bivalent vaccines. The invited papers broadly cover the safety and immunogenicity of COVID-19 vaccines in normal healthy persons, persons with moderate immunocompromised status and persons with severe immunocompromised status.

Dr. Lalit Batra
Dr. Shailendra Kumar Verma
Collection Editors

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the collection website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (2 papers)


Anti-S and Anti-N Antibody Responses of COVID-19 Vaccine Recipients
Vaccines 2023, 11(9), 1398; - 22 Aug 2023
Viewed by 375
The long-term immunoglobulin responses of COVID-19 vaccinations is important to determine the efficacy of these vaccinations. This study aimed to investigate and compare the long-term immunoglobulin response of COVID-19 vaccination recipients, using anti-S IgG, anti-N IgG, and IgM titer levels. This study included [...] Read more.
The long-term immunoglobulin responses of COVID-19 vaccinations is important to determine the efficacy of these vaccinations. This study aimed to investigate and compare the long-term immunoglobulin response of COVID-19 vaccination recipients, using anti-S IgG, anti-N IgG, and IgM titer levels. This study included 267 participants, comprising individuals who tested positive for COVID-19 through PCR testing (n = 125), and those who received the Pfizer (n = 133), Sinopharm (n = 112), AstraZeneca (n = 20), or Sputnik (n = 2) vaccines. Female participants comprised the largest share of this study (n = 147, 55.1%). This study found that most participants had positive IgG antibodies, with 96.3% having anti-S IgG and 75.7% having anti-N IgG. Most participants (90.3%) tested negative for anti-N IgM antibodies. Sinopharm-vaccinated individuals exhibited a notably lower rate of positive anti-S IgG (93.8%) and a significantly higher rate of positive anti-N IgG antibodies (91%). Anti-N IgG levels were significantly correlated with the number of prior COVID-19 infections (p = 0.015). Specifically, individuals with a history of four COVID-19 infections had higher anti-N IgG titers (14.1 ± 1.4) than those with only one experience of COVID-19 infection (9.4 ± 7.2). Individuals who were infected with COVID-19 after receiving the vaccine demonstrated higher levels of anti-N IgG, exhibiting a 25% increase in mean titer levels compared to those who were infected prior to vaccination. There was a statistically significant association between anti-N IgG positivity with age (p = 0.034), and smoking status (p = 0.006) of participants. Participants younger than 20 and older than 60 showed the highest positivity rate of anti-N (>90%). Smokers had a low positivity rate of anti-N (68.8%) compared to nonsmokers (83.6%). In conclusion, this study demonstrated that most COVID-19 vaccination recipients had positive IgG antibodies, with differences in the long-term immunoglobulin response depending on the type of vaccine administered and occurrence of COVID-19 infection. Full article
Show Figures

Figure 1

Safety, Tolerability, and Immunogenicity of COVID-19 Bivalent Vaccination
Vaccines 2023, 11(6), 1040; - 30 May 2023
Viewed by 911
The COVID-19 pandemic has triggered unparalleled global disruption [...] Full article
Back to TopTop